Like_老虎社区_美港股上老虎

lee1234
2021-11-05

Novavax completes process for WHO emergency use approval of COVID-19 vaccine

Nov 4 (Reuters) - Vaccine developer Novavax Inc said on Thursday it has completed the submission pro

Novavax completes process for WHO emergency use approval of COVID-19 vaccine

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":846857943,"tweetId":"846857943","gmtCreate":1636074768830,"gmtModify":1636074769232,"author":{"id":3579516715925048,"idStr":"3579516715925048","authorId":3579516715925048,"authorIdStr":"3579516715925048","name":"lee1234","avatar":"https://static.tigerbbs.com/c1a0ecabeae2d32250fce1eb7e612d3d","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":18,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Like</p></body></html>","htmlText":"<html><head></head><body><p>Like</p></body></html>","text":"Like","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/846857943","repostId":2181970597,"repostType":4,"repost":{"id":"2181970597","kind":"news","pubTimestamp":1636071071,"share":"https://www.laohu8.com/m/news/2181970597?lang=&edition=full","pubTime":"2021-11-05 08:11","market":"us","language":"en","title":"Novavax completes process for WHO emergency use approval of COVID-19 vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2181970597","media":"Reuters","summary":"Nov 4 (Reuters) - Vaccine developer Novavax Inc said on Thursday it has completed the submission pro","content":"<p>Nov 4 (Reuters) - Vaccine developer Novavax Inc said on Thursday it has completed the submission process for emergency use listing of its COVID-19 vaccine candidate with the World Health Organization.</p>\n<p>The company submitted to the health agency all modules required for the evaluation of NVX-CoV2373, its protein-based COVID-19 vaccine, days after receiving its first emergency use authorization from Indonesia.</p>\n<p>The company is also expecting regulators in countries including India and the Philippines to decide on its vaccine within weeks.</p>\n<p>A green light from the WHO would set the stage for Novavax to begin shipping doses to the COVAX program that supplies shots to low-income countries.</p>\n<p>Novavax is prepared to deliver its vaccine globally, Chief Executive Stanley Erck said in a statement. The company said it remains on track to file for U.S. approval by end of the year.</p>\n<p>The Maryland-based vaccine developer reported a bigger net loss of $322.4 million, or $4.31 per share, for the third quarter, compared to $197.3 million a year earlier.</p>\n<p>Revenue rose to $178.8 million, mainly due to increased development activities relating to its COVID vaccine, including services performed under the U.S. government agreement and royalties from licensing pacts. </p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax completes process for WHO emergency use approval of COVID-19 vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax completes process for WHO emergency use approval of COVID-19 vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-05 08:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/1-novavax-completes-process-emergency-203556983.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nov 4 (Reuters) - Vaccine developer Novavax Inc said on Thursday it has completed the submission process for emergency use listing of its COVID-19 vaccine candidate with the World Health Organization....</p>\n\n<a href=\"https://finance.yahoo.com/news/1-novavax-completes-process-emergency-203556983.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://finance.yahoo.com/news/1-novavax-completes-process-emergency-203556983.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2181970597","content_text":"Nov 4 (Reuters) - Vaccine developer Novavax Inc said on Thursday it has completed the submission process for emergency use listing of its COVID-19 vaccine candidate with the World Health Organization.\nThe company submitted to the health agency all modules required for the evaluation of NVX-CoV2373, its protein-based COVID-19 vaccine, days after receiving its first emergency use authorization from Indonesia.\nThe company is also expecting regulators in countries including India and the Philippines to decide on its vaccine within weeks.\nA green light from the WHO would set the stage for Novavax to begin shipping doses to the COVAX program that supplies shots to low-income countries.\nNovavax is prepared to deliver its vaccine globally, Chief Executive Stanley Erck said in a statement. The company said it remains on track to file for U.S. approval by end of the year.\nThe Maryland-based vaccine developer reported a bigger net loss of $322.4 million, or $4.31 per share, for the third quarter, compared to $197.3 million a year earlier.\nRevenue rose to $178.8 million, mainly due to increased development activities relating to its COVID vaccine, including services performed under the U.S. government agreement and royalties from licensing pacts.","news_type":1},"isVote":1,"tweetType":1,"viewCount":729,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}